Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport™

References

• McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006;12:S122–8.
   PubMed Web of Science ®Google Scholar
• Ilie CP, Chancellor MB. Perspective of Botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 2009;19:20–5.
   PubMed Web of Science ®Google Scholar
• Djavan B, Waldert M, Ghawidel C, Marberger M. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004;14:45–50.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 2008;40:921–31.
   PubMed Web of Science ®Google Scholar
• Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000;56:3–6.
   PubMed Web of Science ®Google Scholar
• Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004;45:411–9.
   PubMed Web of Science ®Google Scholar
• Djavan B, Marberger M. Minimally invasive procedures as an alternative to medical management for lower urinary tract symptoms of benign prostatic hyperplasia. Curr Opin Urol 2001;11:1–7.
   PubMedGoogle Scholar
• da Silva CM, Cruz F. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? Curr Opin Urol 2009;19:347–52.
   PubMed Web of Science ®Google Scholar
• Saemi AM, Plante MK. Injectables in the prostate. Curr Opin Urol 2008;18:28–33.
   PubMed Web of Science ®Google Scholar
• Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998;37:44–50.
   PubMed Web of Science ®Google Scholar
• Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008;54:765–75.
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919–22.
   PubMed Web of Science ®Google Scholar
• Kumar V, Templeman L, Chapple CR, Chess-Williams R. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003;13:285–91.
   PubMed Web of Science ®Google Scholar
• Namazi H. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: a molecular mechanism. Urology 2008;72:463–4; author reply 4.
   PubMed Web of Science ®Google Scholar
• Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009;73:90–4.
   PubMed Web of Science ®Google Scholar
• Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999;53:1–6.
   PubMed Web of Science ®Google Scholar
• Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259–64; discussion 64–5.
   PubMed Web of Science ®Google Scholar
• Guercini F, Giannantoni A, Bard RL, Brisinda G, Cadeddu F, Maria G, Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study. J Urol Suppl 2005;173:376–7.
   Web of Science ®Google Scholar
• Kuo HC. Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670–4.
   PubMed Web of Science ®Google Scholar
• Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006;47:706–14.
   PubMed Web of Science ®Google Scholar
• Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008;53:153–9.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Giannantoni A, Chancellor MB. The potential and promise of using botulinum toxin in the prostate gland. BJU Int 2006;98:28–32.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009;43:206–11.
   PubMed Web of Science ®Google Scholar
• Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13(Suppl 4):10–9.
   PubMedGoogle Scholar
• de Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007;9(Suppl 1):17–22.
   PubMedGoogle Scholar
• Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97:1030–4.
   PubMed Web of Science ®Google Scholar
• Rasmussen LN. [Botulinum toxin. Use in the treatment of spasticity in children]. Ugeskr Laeger 2000;162:6557–61.
   PubMedGoogle Scholar
• Grosse J, Kramer G, Tong TQT, Stöhrer M, Jakse G. Efficacy, dosage and safety of Dysport English botulinum toxin A in severe neurogenic detrusor overactivity (NDO). Eur Urol Suppl 2005;4(3):104.
   Web of Science ®Google Scholar
• Ebrahimi A, Radmanesh M. Botulinum toxin type-A (BT-A) for the treatment of multiple eccrine hydrocystomas. J Dermatolog Treat 2009:1–4.
   Web of Science ®Google Scholar
• Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:335–40.
   PubMed Web of Science ®Google Scholar
• Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 2001;168:162–70.
   PubMed Web of Science ®Google Scholar